Irinotecan
Metastatic Gastric Carcinoma
National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Metastatic Gastric Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Talzenna National Cancer Institute (NCI) | Phase 2 | CCC |
Inno-206 City of Hope Medical Center | Phase 1 | CCC |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 1 | CC |
Zn-C3 National Cancer Institute (NCI) | Phase 1 | CC |
Epirubicin M.D. Anderson Cancer Center | Phase 1 | CC |
View all 12 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →